Pharma top of the ROCE league in UK

16 July 2001

Experian, a UK information solutions company, has published a reportwhich shows that, in terms of return on capital employed for the fourth quarter of 2000, the country's pharmaceutical sector came out ahead of all other industries at 26.4%. However, the sector is well down on its peak in the first quarter of 1998, when the average ROCE of drugmakers in the UK was 42.7%.

ROSF less impressive

The report adds that productivity rose sharply in the pharmaceutical sector in the last six months of 2000, but the average return on shareholder funds among the UK's drugs companies has fallen at twice the rate of the industrial average over the last 12 months to 14.9%. It notes that ROSF is now "around half that enjoyed during the mid-1990s, which must call into question whether shareholders' interests have been best served by the mergers and acquisitions of the last few years."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight